Preparation of Cytokine-activated NK Cells for Use in Adoptive Cell Therapy in Cancer Patients: Protocol Optimization and Therapeutic Potential

Author(s):
Ostaijen-ten Dam, M.M. van; Prins, H.J.; Boerman, G.H.; Vervat, C.; Pende, D.; Putter, H.; Lankester, A.; Tol, M.J.D. van (0000-0003-1600-4279); Zwaginga, J.J.; Schilham, M.W. (0000-0003-4391-6003)
Published
2016
Publication type
Article / Letter to editor
interleukin-2interleukin-15natural killer cellsCliniMACSacute leukemiaclinical protocolgood manufacturing practice
Date issued
2016-03-31
Language
English
Is part of
Journal of Immunotherapy (2016), Vol. 39, no. 2, p. 90-100
hdl
1887/106634
doi
10.1097/CJI.0000000000000110